UBS Group’s GSK GSK Stock Holding History

UBS Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$115M	Sell	2,084,235 -4,196,648	-67%	-$227M	0.02%	948
2025 Q4	$308M	Buy	6,280,883 +1,635,448	+35%	+$76.3M	0.05%	372
2025 Q3	$200M	Sell	4,645,435 -592,852	-11%	-$23.2M	0.03%	582
2025 Q2	$201M	Sell	5,238,287 -2,633,768	-33%	-$101M	0.03%	532
2025 Q1	$305M	Buy	7,872,055 +1,388,847	+21%	+$50.8M	0.06%	344
2024 Q4	$219M	Buy	6,483,208 +5,819,167	+876%	+$209M	0.04%	454
2024 Q3	$27.1M	Sell	664,041 -26,985	-4%	-$1.1M	0.01%	1590
2024 Q2	$26.6M	Buy	691,026 +33,562	+5%	+$1.41M	0.01%	1457
2024 Q1	$28.2M	Buy	657,464 +109,022	+20%	+$4.5M	0.01%	1430
2023 Q4	$20.3M	Sell	548,442 -100,834	-16%	-$3.62M	0.01%	1574
2023 Q3	$23.5M	Buy	649,276 +7,429	+1%	+$264K	0.01%	1366
2023 Q2	$22.9M	Sell	641,847 -386,038	-38%	-$13.8M	0.01%	1349
2023 Q1	$36.6M	Sell	1,027,885 -175,844	-15%	-$6.15M	0.01%	964
2022 Q4	$42.3M	Buy	1,203,729 +190,273	+19%	+$6.34M	0.02%	910
2022 Q3	$29.8M	Sell	1,013,456 -8,298	-0.8%	-$314K	0.01%	1007
2022 Q2	$55.6M	Buy	1,021,754 +142,521	+16%	+$7.87M	0.02%	678
2022 Q1	$47.9M	Sell	879,233 -48,009	-5%	-$2.61M	0.02%	870
2021 Q4	$51.1M	Sell	927,242 -4,863,910	-84%	-$253M	0.01%	948
2021 Q3	$277M	Sell	5,791,152 -161,621	-3%	-$8.12M	0.09%	229
2021 Q2	$296M	Sell	5,952,773 -769,531	-11%	-$37M	0.1%	210
2021 Q1	$300M	Buy	6,722,304 +5,618,993	+509%	+$255M	0.1%	206
2020 Q4	$50.8M	Sell	1,103,311 -10,155	-0.9%	-$466K	0.02%	777
2020 Q3	$52.4M	Sell	1,113,466 -74,688	-6%	-$3.74M	0.02%	634
2020 Q2	$60.6M	Sell	1,188,154 -47,905	-4%	-$2.46M	0.03%	530
2020 Q1	$58.5M	Buy	1,236,059 +104,057	+9%	+$5.55M	0.03%	487
2019 Q4	$66.5M	Buy	1,132,002 +5,440	+0.5%	+$303K	0.02%	609
2019 Q3	$60.1M	Buy	1,126,562 +139,932	+14%	+$7.2M	0.02%	595
2019 Q2	$49.4M	Sell	986,630 -65,207	-6%	-$3.27M	0.02%	676
2019 Q1	$54.9M	Sell	1,051,837 -88,625	-8%	-$4.43M	0.02%	592
2018 Q4	$54.5M	Sell	1,140,462 -46,068	-4%	-$2.27M	0.02%	563
2018 Q3	$59.6M	Buy	1,186,530 +11,734	+1%	+$596K	0.02%	600
2018 Q2	$59.2M	Sell	1,174,796 -81,534	-6%	-$4.11M	0.03%	572
2018 Q1	$61.4M	Buy	1,256,330 +107,132	+9%	+$4.99M	0.03%	543
2017 Q4	$51M	Sell	1,149,198 -66,376	-5%	-$3.07M	0.02%	664
2017 Q3	$61.7M	Sell	1,215,574 -534,103	-31%	-$27.1M	0.03%	523
2017 Q2	$94.3M	Buy	1,749,677 +26,516	+2%	+$1.41M	0.05%	368
2017 Q1	$90.8M	Buy	1,723,161 +65,453	+4%	+$3.32M	0.05%	362
2016 Q4	$79.8M	Sell	1,657,708 -166,909	-9%	-$8.24M	0.04%	393
2016 Q3	$98.4M	Buy	1,824,617 +97,835	+6%	+$5.36M	0.06%	326
2016 Q2	$93.5M	Buy	1,726,782 +110,410	+7%	+$5.82M	0.06%	324
2016 Q1	$81.9M	Sell	1,616,372 -48,087	-3%	-$2.4M	0.05%	326
2015 Q4	$84M	Sell	1,664,459 -59,643	-3%	-$3.04M	0.05%	350
2015 Q3	$82.9M	Sell	1,724,102 -174,024	-9%	-$9.06M	0.06%	326
2015 Q2	$98.8M	Buy	1,898,126 +113,246	+6%	+$6.38M	0.07%	309
2015 Q1	$103M	Buy	1,784,880 +379,411	+27%	+$21.8M	0.07%	297
2014 Q4	$75.1M	Buy	+1,405,469	New	+$78.6M	0.05%	377

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group's GSK Position: Q1 2026 in Review

UBS Group reduced its GSK (GSK) stake by 67% in Q1 2026, selling an estimated $227M and leaving 2,084,235 shares worth $115M. The position accounts for 0.02% of the portfolio, ranked #948.

UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since. The position peaked at $308M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

UBS Group held 2,084,235 shares of GSK worth $115M as of Q1 2026.
UBS Group sold 4,196,648 GSK shares in Q1 2026, an estimated $227M.
GSK made up 0.02% of UBS Group's portfolio in Q1 2026, its #948 holding.
UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since.
UBS Group's GSK position peaked at $308M in Q4 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.